Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Lynn Miesel"'
Publikováno v:
Pharmacology Research & Perspectives, Vol 7, Iss 6, Pp n/a-n/a (2019)
Abstract Rezafungin acetate is a novel echinocandin in clinical development for prevention and treatment of invasive fungal infections. Rezafungin is differentiated by a pharmacokinetic/pharmacodynamic (PK/PD) profile that includes a long half‐life
Externí odkaz:
https://doaj.org/article/45ab665ee63e41fbac2adf1b76ea1d2b
Autor:
Sheo B. Singh, Lynn Miesel, Susanne Kramer, Libo Xu, Fangbio Li, Jing Lan, Phillip Lipari, Jon D. Polishook, Gongjie Liu, Lianzhu Liang, Amy M. Flattery
Publikováno v:
Journal of Natural Products. 85:1141-1146
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f16986d209b477a221d92f1a8fa4a761
https://doi.org/10.1021/acs.jnatprod.2c00093
https://doi.org/10.1021/acs.jnatprod.2c00093
Autor:
Sheo B. Singh, Christopher M. Tan, David Kaelin, Peter T. Meinke, Lynn Miesel, David B. Olsen, Hideyuki Fukuda, Ryuta Kishii, Masaya Takei, Kohei Ohata, Tomoko Takeuchi, Taku Shibue, Hisashi Takano, Akinori Nishimura, Yasumichi Fukuda
Publikováno v:
Bioorganicmedicinal chemistry letters. 75
Novel bacterial topoisomerase inhibitors (NBTIs) are the newest members of gyrase inhibitor broad-spectrum antibacterial agents, represented by the most advanced member, gepotidacin, a 4-amino-piperidine linked NBTI, which is undergoing phase III cli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c88fe127252145bd1368ad8cd0c89f1d
https://pubmed.ncbi.nlm.nih.gov/35609741
https://pubmed.ncbi.nlm.nih.gov/35609741
Publikováno v:
Antimicrobial Agents and Chemotherapy
Antifungal prophylaxis is recommended to prevent invasive fungal disease caused by Candida spp., Aspergillus spp., and Pneumocystis jirovecii in patients at risk for opportunistic infections, such as allogeneic blood or marrow transplant recipients,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bd1be0fa8d15aaee34c66bfa5854b51
http://europepmc.org/articles/PMC8092522
http://europepmc.org/articles/PMC8092522
Autor:
Abhay Joshi, Jürgen B. Bulitta, Binh An Diep, John Farley, Alexander J. Lepak, Ursula Waack, James M Byrne, Thomas J. Walsh, Edward A. Weinstein, Andrew J Phipps, Lynn Miesel, Dmitri Iarikov, Matthew B. Lawrenz, Simone M Shurland, Brian Luna, William W. Hope, Tina Guina, Thushi Amini, William J. Weiss
Publikováno v:
Antimicrob Agents Chemother
The U.S. Food and Drug Administration (FDA) hosted a public workshop entitled “Advancing Animal Models for Antibacterial Drug Development” on 5 March 2020. The workshop mainly focused on models of pneumonia caused by Pseudomonas aeruginosa and Ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6dfcc2472fa1301107743b26a24e0218
https://pubmed.ncbi.nlm.nih.gov/33106262
https://pubmed.ncbi.nlm.nih.gov/33106262
Autor:
Lee Swem, Alisa W Serio, Chris M. Pillar, Amanda Burek, Danielle Hall, Frederick Cohen, Ryan Cirz, Kevin M. Krause, Eliana Saxon Armstrong, Christy M. Hebner, Adrian Jubb, Lynn Miesel, Grace Lee, Vincent Nieto, Mary Thwaites, Darrin Hildebrandt, Cat M. Haglund, Machajewski Timothy D, Timothy R. Kane, Meredith Hackel, Logan D. Andrews
Publikováno v:
Antimicrobial Agents and Chemotherapy. 63
New drugs with novel mechanisms of resistance are desperately needed to address both community and nosocomial infections due to Gram-negative bacteria. One such potential target is LpxC, an essential enzyme that catalyzes the first committed step of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aacedbcf86b22e6e1952bd3b6c32722d
https://doi.org/10.1128/aac.00977-19
https://doi.org/10.1128/aac.00977-19
Autor:
Kevin M, Krause, Cat M, Haglund, Christy, Hebner, Alisa W, Serio, Grace, Lee, Vincent, Nieto, Frederick, Cohen, Timothy R, Kane, Timothy D, Machajewski, Darrin, Hildebrandt, Chris, Pillar, Mary, Thwaites, Danielle, Hall, Lynn, Miesel, Meredith, Hackel, Amanda, Burek, Logan D, Andrews, Eliana, Armstrong, Lee, Swem, Adrian, Jubb, Ryan T, Cirz
Publikováno v:
Antimicrobial agents and chemotherapy. 63(11)
New drugs with novel mechanisms of resistance are desperately needed to address both community and nosocomial infections due to Gram-negative bacteria. One such potential target is LpxC, an essential enzyme that catalyzes the first committed step of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e018c1e74a4ab5cd3628401115df7b3a
https://pubmed.ncbi.nlm.nih.gov/31451507
https://pubmed.ncbi.nlm.nih.gov/31451507
Autor:
Jingjun Yin, Kouhei Oohata, Peter T. Meinke, Armando Lagrutta, David E. Kaelin, Lynn Miesel, Charles Gill, Hideyuki Fukuda, Charles G. Garlisi, Sheo B. Singh, Yasumichi Fukuda, Christopher M. Tan, Toussaint Nathalie Y, Taku Shibue, Tomoko Takeuchi, Hisashi Takano, Ryuta Kishii, Masaya Takei, David B. Olsen, Akinori Nishimura, Jin Wu, Takayuki Tsuchiya
Publikováno v:
Antimicrobial Agents and Chemotherapy. 60:4830-4839
Oxabicyclooctane-linked novel bacterial topoisomerase inhibitors (NBTIs) represent a new class of recently described antibacterial agents with broad-spectrum activity. NBTIs dually inhibit the clinically validated bacterial targets DNA gyrase and top
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d13383dbf940731b0d5857d379597c7
https://doi.org/10.1128/aac.00619-16
https://doi.org/10.1128/aac.00619-16
Autor:
Lynn Miesel, Clive A. Prestidge, Dean L Shinabarger, Deb Sweeney, Ramiz A. Boulos, Shasha Rao
Publikováno v:
The Journal of Antibiotics
Antibiotic-resistant bacteria is a major threat to human health and is predicted to become the leading cause of death from disease by 2050. Despite the recent resurgence of research and development in the area, few antibiotics have reached the market
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08fb3ccbe8df6bd46fb14701867c5d60
https://doi.org/10.1038/ja.2016.45
https://doi.org/10.1038/ja.2016.45
Autor:
Lynn Miesel, Akinori Nishimura, Masanobu Yajima, Peter T. Meinke, Christopher M. Tan, Kohei Ohata, Xiu Wang, Sheo B. Singh, Yonggang Liao, David B. Olsen, Masaya Takei, Changqing Wei, Taku Shibue, Takeshi Shibata, Hideyuki Fukuda, Armando Lagrutta, David E. Kaelin, Xuanjia Peng, Yasumichi Fukuda, Jin Wu, Ryuta Kishii
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 25:3636-3643
Oxabicyclooctane linked 1,5-naphthyridinyl-pyridoxazinones are novel broad-spectrum bacterial topoisomerase inhibitors (NBTIs) targeting bacterial DNA gyrase and topoisomerase IV at a site different than quinolones. Due to lack of cross-resistance to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab2677d36308cca1fc4c26269ddc1514
https://doi.org/10.1016/j.bmcl.2015.06.057
https://doi.org/10.1016/j.bmcl.2015.06.057